
Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
Japanese drugmaker Nippon Shinyaku announced that its Duchenne muscular dystrophy drug, Viltepso, failed to meet its primary endpoint in a placebo-controlled confirmatory trial. The drug, part of a class of treatments for the rare disease called exon-skippers, did not show statistically significant differences compared to the placebo in terms of improving muscle function. Although children…